New lung cancer study reveals how QSOX2 fuels drug resistance to osimertinib

A 2026 study in Cell Death Discovery has uncovered a new mechanism behind drug resistance in lung cancer. Researchers found that the QSOX2 protein, previously known for its enzymatic role, also operates in a non-enzymatic way to help cancer cells evade treatment. This discovery sheds light on why some patients with EGFR-mutant lung adenocarcinoma respond poorly to the drug osimertinib.

The findings suggest that QSOX2 interacts with the transcription factor JUNB, altering the expression of ITGB4—a protein linked to cancer cell survival. High levels of QSOX2 were associated with worse outcomes for patients on osimertinib, including reduced survival rates. The study focused on how QSOX2 contributes to resistance against osimertinib, a common treatment for EGFR-mutant lung adenocarcinoma. Unlike its known enzymatic function, QSOX2 was shown to regulate the JUNB-ITGB4 signalling pathway. This interaction makes cancer cells more evasive, reducing the drug's effectiveness.

Researchers noted that patients with elevated QSOX2 levels had a weaker response to osimertinib and shorter survival times. The protein's dual role—both enzymatic and non-enzymatic—challenges traditional views of how proteins influence cancer progression. The team emphasised that understanding these alternative functions could be key to overcoming resistance.

As of April 2026, no clinical or preclinical trials have tested inhibitors targeting the QSOX2-JUNB-ITGB4 pathway alongside osimertinib. While the pathway has been discussed in lung cancer research, concrete data on combination treatments remain absent. The study proposes that future work should explore inhibitors for this axis, potentially improving outcomes when paired with existing EGFR therapies.

The authors also called for clinical trials to assess combinatorial strategies. Such research could pave the way for more personalised treatments in EGFR-mutant lung adenocarcinoma, addressing resistance mechanisms that current therapies fail to target. The study highlights a critical gap in treating osimertinib-resistant lung cancer. By targeting the QSOX2-JUNB-ITGB4 axis, researchers hope to develop new combination therapies that improve patient responses. Until clinical trials begin, however, this approach remains an unexplored frontier in oncology.

For now, the findings underscore the need to look beyond traditional enzyme activity when studying drug resistance. This shift in perspective may lead to more effective treatments for patients with limited options.